Breast and Ovarian Cancers: Large Study Improves Estimates of Genetic Risk

Curated by Claudia Shannon / Research Scientist / ishonest

The study – led by the University of Cambridge in the United Kingdom – is reported in JAMA.

The findings should help doctors to improve the advice and counseling they give on treatment options and risk-reducing lifestyle changes, suggest the researchers.

ishonest No.501 - Frizzy Hair

Recommended
No.501 - Frizzy Hair

Cancer develops because of changes to genes that regulate the way that cells work, grow, and divide, causing them to get out of control.

Some of the genetic changes that lead to cancer are inherited, while others can arise during a person’s lifetime, due to either copy errors or environmental factors – such as exposure to tobacco smoke and radiation – that damage DNA.

Higher risks from BRCA1 and BRCA2

Often, it is an accumulation of hundreds of genetic changes – each of which raises a person’s risk by a small amount – that causes cancer.

However, there are some genes, such as BRCA1 and BRCA2, where we know that mutations or errors in their code can greatly increase the risk of breast and ovarian cancer.

Anti-Aging for Summers

Learn more

Normally, BRCA1 and BRCA2 help to protect against cancer, but certain mutations in one or both of the genes make cells “more likely to divide and change” more rapidly, giving rise to cancer.

The reason that the new study is significant is that until now, all risk assessments for patients with BRCA1 and BRCA2 mutations have relied on the results of “retrospective” studies – that is, those that look back on groups of patients who already have the disease.

Being “after the fact,” retrospective studies are prone to inherent problems such as bias and inaccuracies in recording and reporting of the desired information.

The new study is a prospective cohort study – it recruited a large group of nearly 10,000 cancer-free women with risk versions of BRCA1 and BRCA2 and followed them over a period, during which some of the women developed breast and ovarian cancer, while some did not.

ishonest No.232 - Pigmentation & Blemishes

Recommended
No.232 - Pigmentation & Blemishes

Previous prospective studies of BRCA1 and BRCA2 have been done, but they have been very small – for example, the largest one had just 64 cases of breast cancer.

Age-related risk profiles

When they analyzed the results, Dr. Antoniou and colleagues found that for carriers of BRCA1 mutations, the rates of breast cancer rose rapidly until the age of 30 to 40 years and then remained at the same level until the age of 80.

In the case of BRCA2 mutation carriers, the rates of breast cancer rose rapidly until the age of 40 to 50 years, and then also stayed at the same level until the age of 80.

The team found that the risk of developing breast cancer before the age of 80 was 72 percent for women carrying a faulty BRCA1 gene, and 69 percent for women carrying a faulty BRCA2 gene.

What cause uneven skin tone and how to treat it?

Learn more

Similarly, the researchers found that the risk of developing ovarian cancer before the age of 80 was 44 percent for women carrying a faulty BRCA1 gene, and 17 percent for women carrying a faulty BRCA2 gene.

The risk of contralateral breast cancer – or developing cancer in the opposite breast – 20 years after having it diagnosed in the first breast was found to be 40 percent for carriers of a faulty BRCA1 gene, and 26 percent for carriers of a faulty BRCA2 gene.

However, in both breast and ovarian cancer, having a family history such as a relative diagnosed with one of the cancers would raise the risk. The amount of increase went up with the number of first- and second-degree relatives diagnosed with breast cancer.

Finally, the researchers discovered that the degree of cancer risk varies by position of the mutation within the BRCA1 or BRCA2 gene.

Clinically Proven Efficacy for Softer, Smoother, Brighter Skin. Take the free test

Learn more

Dr. Charles Shapiro, director of Cancer Survivorship and Director of Translational Breast Cancer and Research at the Tisch Cancer Institute at Mount Sinai in New York City, NY, comments on the value of the new study:

“A single-institution [study] has too few of these women with inherited germ- line mutations to have sufficient numbers for valid statistical analysis. However, this study pooled the several results of several institutions leading to a relatively large sample. This combined analysis means there is more confidence in the results.”

Learn how a BRCA1 mutation may raise risk of aggressive endometrial cancer.

Read more on: cancers


Learn about unknown needs of your skin for free